Background

Dengue virus (DENV) infection, caused by one of the four serotypes of the virus transmitted primarily by Aedes mosquitoes, poses significant global health challenges. Despite its widespread prevalence, particularly in tropical and subtropical regions, several critical unmet needs persist in the clinical and therapeutic management of dengue

There are currently no FDA-approved antiviral drugs specifically for the treatment of dengue. While supportive care remains the standard treatment, specific antivirals that can effectively inhibit the virus and reduce the duration and severity of symptoms are urgently needed

Vaccines that are safe and effective for individuals regardless of their previous infection status, including those who are seronegative, and that provide balanced protection against all four dengue virus serotypes.